查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2153492

全球鐮狀細胞疾病治療市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

Global Sickle Cell Disease Treatment Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 242 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

全球鐮狀細胞疾病 (SCD) 治療市場預計將從 2025 年的 46.5 億美元成長至 2034 年的 224.8 億美元，2026 年至 2034 年的複合年成長率 (CAGR) 為 19.12%。隨著人們對 SCD 的認知和診斷率的提高，全球 SCD 治療市場不斷擴張。鐮狀的治療方法主要包括緩解疼痛和輸血，而如今，治療方法已發展到包括緩解疾病藥物和先進的生物製藥。研發投入的增加和孤兒藥的激勵措施正在加速創新，尤其是在基因療法和根治性療法領域。

關鍵成長要素包括特定地區盛行率上升、新生兒篩檢計畫改善以及針對罕見疾病的有利法規結構。基因編輯技術和造血幹細胞移植的進步正在開闢新的治療途徑。製藥公司正在投資研發標靶治療，以減少閉塞性發作並提高患者的生活品質。

基因療法具有長期治癒疾病的潛力，其商業化前景十分廣闊。然而，高昂的治療費用和醫療資源分配不均可能阻礙該療法的廣泛應用。為了在未來幾年實現持續成長，新興市場必須擴大醫療基礎設施建設並加強保險報銷。

我們的報告經過精心撰寫，旨在提供涵蓋廣泛行業和市場的全面且切實可行的洞察。每份報告都包含幾個關鍵組成部分，旨在幫助您全面了解市場環境：

市場概覽：本節對市場進行了清晰的說明，包括關鍵定義、分類以及當前行業格局的概述。

市場動態：對影響市場成長的主要促進因素、限制因素、機會和挑戰進行詳細評估。這包括技術發展、法律規範和不斷變化的行業趨勢等因素。

市場區隔分析：本部分依據產品類型、應用、最終使用者和地區，將市場系統性地分類為若干關鍵細分市場。本部分揭示了每個細分市場的表現、成長潛力和市場貢獻。

競爭格局：我們對主要市場參與企業進行了詳細評估，包括其市場定位、產品系列、策略舉措和財務表現。這有助於深入了解競爭趨勢和主要參與者所採取的策略。

市場預測：本部分提供基於數據的市場規模和成長模式預測，預測期為特定時期。它綜合考慮了歷史趨勢、當前市場狀況和定量分析，以識別未來預期趨勢。

區域分析：這包括對主要地理區域的市場表現進行全面檢驗，確定高成長領域和區域趨勢，以更深入地了解每個區域特有的市場機會。

新趨勢與新機會：識別關鍵市場趨勢、技術進步和新興投資機會。本部分重點在於潛在成長領域和未來產業趨勢。

客製化選項：我們提供靈活的報告客製化服務，以滿足您的特定需求。這包括額外的細分、國家/地區分析、競爭對手分析、客製化資料點或針對特定細分市場的洞察，以更好地支援您的策略決策。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 滲透率和成長前景分析
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制因素
    • 市場機遇
    • 市場挑戰
  • 波特五力分析
  • PESTLE分析

第4章：全球鐮狀細胞疾病治療市場：依藥物類別分類

  • 市場分析、洞察與預測
  • 抗代謝物
  • 胺基酸
  • NSAIDs
  • 單株抗體
  • 其他（止痛藥、退燒藥等）

第5章 全球鐮狀細胞疾病治療市場：依疾病類型分類

  • 市場分析、洞察與預測
  • 血紅素SS（HbSS）
  • SC血紅素（HbSC）
  • 血紅素 (HbS) BETA-地中海型貧血

第6章 全球鐮狀細胞疾病治療市場：依年齡層分類

  • 市場分析、洞察與預測
  • 孩子們
  • 成人

第7章 全球鐮狀細胞疾病治療市場：依給藥途徑分類

  • 市場分析、洞察與預測
  • 口服
  • 腸外

第8章 全球鐮狀細胞疾病治療市場：依通路分類

  • 市場分析、洞察與預測
  • 醫院藥房
  • 零售藥房
  • 網路藥房

第9章 全球鐮狀細胞疾病治療市場：依地區分類

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 中國
    • 日本
    • 韓國
    • 印度
    • 澳洲
    • 東南亞
    • 其他亞太國家
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中東和非洲國家

第10章 競爭格局

  • 最新趨勢
  • 公司分類
  • 供應鏈和銷售管道合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商情況（基於現有資訊）
  • 策略規劃

第11章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • Novartis
    • Pfizer
    • Bristol Myers Squibb
    • Global Blood Therapeutics
    • Novo Nordisk
    • Agios Pharmaceuticals
    • Vertex Pharmaceuticals
    • Bluebird Bio
    • Editas Medicine
    • CRISPR Therapeutics
    • Beam Therapeutics
    • Sangamo Therapeutics
    • Chiesi Farmaceutici
    • Emmaus Life Sciences
    • Cyclacel Pharmaceuticals
    • Fulcrum Therapeutics
    • Forma Therapeutics
    • Bioverativ
    • Roche
    • Sanofi
簡介目錄
Product Code: VMR11210465

The global sickle cell disease treatment market size is expected to reach USD 22.48 Billion in 2034 from USD 4.65 Billion in 2025, growing at a CAGR of 19.12% during 2026-2034.The sickle cell disease (SCD) treatment market has expanded as awareness and diagnosis rates improve globally. Traditionally managed with pain-relief therapies and blood transfusions, treatment approaches have evolved to include disease-modifying drugs and advanced biologics. Increasing research investment and orphan drug incentives have accelerated innovation, particularly in gene therapy and curative approaches.

Major growth drivers include rising prevalence in certain geographic regions, improved newborn screening programs, and supportive regulatory frameworks for rare diseases. Advances in gene-editing technologies and hematopoietic stem cell transplantation have opened new therapeutic possibilities. Pharmaceutical companies are investing in targeted therapies that reduce vaso-occlusive crises and improve patient quality of life.

Future prospects are highly promising with the commercialization of gene therapies offering potential long-term cures. However, high treatment costs and access disparities may challenge widespread adoption. Expanding healthcare infrastructure and reimbursement support in emerging markets will be crucial for sustainable growth in the coming years.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Drug Class

  • Antimetabolites
  • AminAcids
  • NSAIDs
  • Monoclonal Antibodies
  • Others (Analgesis and Antipyretics, etc)

By Disease Type

  • Hemoglobin S5 (HbSS)
  • Hemoglobin SC (HbSC)
  • Hemoglobin (HbS) beta thalassemia

By Age-Group

  • Children
  • Adults

By Route of Administration

  • Oral
  • Parenteral

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

COMPANIES PROFILED

  • Novartis, Pfizer, Bristol Myers Squibb, Global Blood Therapeutics, Novo Nordisk, Agios Pharmaceuticals, Vertex Pharmaceuticals, bluebird bio, Editas Medicine, CRISPR Therapeutics, Beam Therapeutics, Sangamo Therapeutics, Chiesi Farmaceutici, Emmaus Life Sciences, Cyclacel Pharmaceuticals, Fulcrum Therapeutics, Forma Therapeutics, Bioverativ, Roche, Sanofi

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET: BY DRUG CLASS 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Drug Class
  • 4.2. Antimetabolites Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. AminAcids Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.4. NSAIDs Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.5. Monoclonal Antibodies Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.6. Others (Analgesis and Antipyretics, etc) Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET: BY DISEASE TYPE 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Disease Type
  • 5.2. Hemoglobin S5 (HbSS) Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Hemoglobin SC (HbSC) Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.4. Hemoglobin (HbS) beta thalassemia Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET: BY AGE-GROUP 2022-2034 (USD MN)

  • 6.1. Market Analysis, Insights and Forecast Age-group
  • 6.2. Children Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.3. Adults Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

  • 7.1. Market Analysis, Insights and Forecast Route Of Administration
  • 7.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.3. Parenteral Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

  • 8.1. Market Analysis, Insights and Forecast Distribution Channel
  • 8.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 8.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 8.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET: BY REGION 2022-2034 (USD MN)

  • 9.1. Regional Outlook
  • 9.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 9.2.1 By Drug Class
    • 9.2.2 By Disease Type
    • 9.2.3 By Age-group
    • 9.2.4 By Route Of Administration
    • 9.2.5 By Distribution Channel
    • 9.2.6 United States
    • 9.2.7 Canada
    • 9.2.8 Mexico
  • 9.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 9.3.1 By Drug Class
    • 9.3.2 By Disease Type
    • 9.3.3 By Age-group
    • 9.3.4 By Route Of Administration
    • 9.3.5 By Distribution Channel
    • 9.3.6 United Kingdom
    • 9.3.7 France
    • 9.3.8 Germany
    • 9.3.9 Italy
    • 9.3.10 Spain
    • 9.3.11 Russia
    • 9.3.12 Rest Of Europe
  • 9.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 9.4.1 By Drug Class
    • 9.4.2 By Disease Type
    • 9.4.3 By Age-group
    • 9.4.4 By Route Of Administration
    • 9.4.5 By Distribution Channel
    • 9.4.6 China
    • 9.4.7 Japan
    • 9.4.8 South Korea
    • 9.4.9 India
    • 9.4.10 Australia
    • 9.4.11 South East Asia
    • 9.4.12 Rest Of Asia Pacific
  • 9.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 9.5.1 By Drug Class
    • 9.5.2 By Disease Type
    • 9.5.3 By Age-group
    • 9.5.4 By Route Of Administration
    • 9.5.5 By Distribution Channel
    • 9.5.6 Brazil
    • 9.5.7 Argentina
    • 9.5.8 Peru
    • 9.5.9 Chile
    • 9.5.10 Rest of Latin America
  • 9.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 9.6.1 By Drug Class
    • 9.6.2 By Disease Type
    • 9.6.3 By Age-group
    • 9.6.4 By Route Of Administration
    • 9.6.5 By Distribution Channel
    • 9.6.6 Saudi Arabia
    • 9.6.7 UAE
    • 9.6.8 Israel
    • 9.6.9 South Africa
    • 9.6.10 Rest of the Middle East And Africa

Chapter 10. COMPETITIVE LANDSCAPE

  • 10.1. Recent Developments
  • 10.2. Company Categorization
  • 10.3. Supply Chain & Channel Partners (based on availability)
  • 10.4. Market Share & Positioning Analysis (based on availability)
  • 10.5. Vendor Landscape (based on availability)
  • 10.6. Strategy Mapping

Chapter 11. COMPANY PROFILES OF GLOBAL SICKLE CELL DISEASE TREATMENT INDUSTRY

  • 11.1. Top Companies Market Share Analysis
  • 11.2. Company Profiles
    • 11.2.1 Novartis
    • 11.2.2 Pfizer
    • 11.2.3 Bristol Myers Squibb
    • 11.2.4 Global Blood Therapeutics
    • 11.2.5 Novo Nordisk
    • 11.2.6 Agios Pharmaceuticals
    • 11.2.7 Vertex Pharmaceuticals
    • 11.2.8 Bluebird Bio
    • 11.2.9 Editas Medicine
    • 11.2.10 CRISPR Therapeutics
    • 11.2.11 Beam Therapeutics
    • 11.2.12 Sangamo Therapeutics
    • 11.2.13 Chiesi Farmaceutici
    • 11.2.14 Emmaus Life Sciences
    • 11.2.15 Cyclacel Pharmaceuticals
    • 11.2.16 Fulcrum Therapeutics
    • 11.2.17 Forma Therapeutics
    • 11.2.18 Bioverativ
    • 11.2.19 Roche
    • 11.2.20 Sanofi